Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALLGregory W. Roloff, George Yaghmour, Simone E. Dekker et al.|Journal of Clinical Oncology|2024Cited by 36
NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free SurvivalYannis K. Valtis, Aaron C. Logan, David Nemirovsky et al.|Transplantation and Cellular Therapy|2025Cited by 0